Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Under the terms of the agreement, Redfin shareholders will receive 0.7926 shares of Rocket Class A common stock for each Redfin share—a 63% premium over Redfin’s 30-day volume-weighted average price.

On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...

Protagonist Therapeutics shares were up 28% to $49.25 after the company reported positive topline results from a Phase 2b study of icotrokinra, conducted by partner Johnson & Johnson.

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Protagonist Therapeutics (PTGX – Research Report) today. The company’s ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Protagonist Therapeutics (PTGX – Research Report) and Roche ...

Takeda and Protagonist Therapeutics have shared positive top-line results from a phase 3 trial of rusfertide in the rare ...

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its price target upped by analysts at JPMorgan Chase & Co. from ...

We have the answer for Protagonist of the Metroid video-game series crossword clue that will help you solve the crossword puzzle you're working on!

HC Wainwright restated their buy rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research report released on Monday morning,Benzinga reports. They currently have a $54.00 ...

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX ) and Takeda (TSE:4502/NYSE:TAK ) today announced positive ...